Verona: New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD

 

• PDUFA Target Action Date of June 26, 2024
• Ensifentrine, if approved, is expected to be the first novel mechanism available for the maintenance treatment of COPD in more than a decade

https://www.biospace.com/article/releases/verona-pharma-announces-the-us-fda-has-accepted-the-new-drug-application-filing-for-ensifentrine-for-the-maintenance-treatment-of-copd/